Physician
Presbyterian Healthcare Services
Presbyterian Healthcare Services was paid $8.49M by Medicaid between Jan 2018 and Dec 2024, across 101 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoPRESBYTERIAN HEALTHCARE SERVICES
TUCUMCARI, NM 88401
TUCUMCARI, NM 88401
33aNPI1962488304assigned 12/19/2005
33bProvider typeEmergency Medicine Physician
28Total paid$8.49M
24GClaims100,825
24DCodes billed101
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in New Mexico
Rank by total paid#10 of 39
Median peer was paid$669K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,066 | $1.48M | |
| 2019 | 14,385 | $1.04M | |
| 2020 | 5,457 | $564K | |
| 2021 | 10,334 | $775K | |
| 2022 | 14,825 | $1.16M | |
| 2023 | 18,903 | $1.79M | |
| 2024incomplete | 15,855 | $1.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 6,615 | 6,306 | $1.73M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 4,233 | 3,918 | $1.49M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 2,785 | 2,549 | $1.34M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.4% | 7,674 | 2,035 | $457K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 537 | 525 | $357K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.5% | 1,846 | 1,782 | $294K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.5% | 2,880 | 2,466 | $293K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 3.1% | 5,490 | 1,641 | $265K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 2,668 | 2,392 | $167K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 2,077 | 1,797 | $149K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 1,510 | 1,445 | $143K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 451 | 436 | $133K |
89 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 789 | $127K |
| 80053 | Comprehensive metabolic panel | 1.5% | 7,766 | $127K |
| 87631 | 1.4% | 638 | $119K | |
| 71045 | Radiologic examination, chest; single view | 1.4% | 1,708 | $115K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 3,484 | $115K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 567 | $99K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,925 | $78K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 432 | $76K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,432 | $67K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,710 | $65K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 806 | $53K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 374 | $49K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,552 | $46K |
| 73562 | <1% | 312 | $45K | |
| 84484 | <1% | 2,185 | $39K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,090 | $27K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,164 | $26K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 354 | $25K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 940 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,896 | $21K |
| 83690 | <1% | 1,933 | $20K | |
| 73630 | <1% | 176 | $19K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 80 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,528 | $17K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 38 | $17K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 267 | $16K |
| 80306 | <1% | 515 | $15K | |
| 81001 | <1% | 2,359 | $15K | |
| 73610 | <1% | 89 | $14K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 909 | $14K |
| 72110 | <1% | 77 | $12K | |
| 83605 | <1% | 832 | $12K | |
| J3490 | Unclassified drugs | <1% | 2,550 | $10K |
| 73130 | <1% | 89 | $9K | |
| 83880 | <1% | 272 | $8K | |
| 81025 | <1% | 595 | $7K | |
| 83735 | <1% | 891 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 542 | $6K |
| 85027 | <1% | 548 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 168 | $6K |
| 81003 | <1% | 940 | $5K | |
| 82077 | <1% | 279 | $5K | |
| 85610 | <1% | 678 | $5K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,170 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $4K |
| 80061 | Lipid panel | <1% | 253 | $4K |
| 87040 | <1% | 251 | $4K | |
| 97161 | <1% | 77 | $3K | |
| 87081 | <1% | 347 | $3K | |
| 87077 | <1% | 283 | $3K | |
| 84439 | <1% | 274 | $3K | |
| 73030 | <1% | 27 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 150 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 180 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 920 | $3K |
| 86140 | <1% | 366 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 27 | $2K |
| 97162 | <1% | 24 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 24 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 91 | $2K |
| 85379 | <1% | 101 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 17 | $1K |
| 36000 | <1% | 116 | $1K | |
| 87186 | <1% | 104 | $1K | |
| 73110 | <1% | 12 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 634 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 24 | $1K |
| 85018 | <1% | 290 | $976.95 | |
| 96376 | <1% | 19 | $942.14 | |
| 82805 | <1% | 12 | $875.19 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 192 | $802.51 |
| 90715 | <1% | 25 | $590.01 | |
| 97035 | <1% | 28 | $579.13 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 32 | $487.22 |
| 87650 | <1% | 13 | $413.45 | |
| 82550 | <1% | 40 | $397.96 | |
| 84703 | <1% | 26 | $358.87 | |
| 87430 | <1% | 15 | $340.71 | |
| 82962 | <1% | 85 | $292.32 | |
| 85652 | <1% | 28 | $220.89 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 34 | $157.74 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 58 | $129.81 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 15 | $128.69 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 84 | $118.58 |
| 82043 | <1% | 13 | $110.41 | |
| 82570 | <1% | 13 | $96.17 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 34 | $58.46 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12 | $8.79 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMAXWELL, DALE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Presbyterian Healthcare Services | Albuquerque, NM | $3.30M |
| Presbyterian Healthcare Services | Albuquerque, NM | $1.06M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.